Heron Therapeutics (HRTX) Income from Continuing Operations (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Income from Continuing Operations came in at 7402000.0 in Q1 2026, down 416.05% YoY from 2342000.0 in Q1 2025, and down 42.18% on a QoQ basis from 5206000.0 in Q4 2025.
Heron Therapeutics (HRTX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Income from Continuing Operations data on file, last reported at 7402000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 416.05% year-over-year to 7402000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 22239000.0 (down 261.55% YoY) and the FY2025 annual result came in at 415589000.0, down 2866.37% from the prior year.
- Income from Continuing Operations declined to 7402000.0 in Q1 2026, from 5206000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4064000.0 in Q4 2024 to a low of 63625000.0 in Q1 2022.
- A 5-year average of 19216529.41 and a median of 7402000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 141.69% — and 2026, when it tumbled 416.05%.
- Tracing HRTX's Income from Continuing Operations over 5 years: stood at 21666000.0 in 2022, then surged by 44.72% to 11977000.0 in 2023, then soared by 133.93% to 4064000.0 in 2024, then plunged by 228.1% to 5206000.0 in 2025, then tumbled by 42.18% to 7402000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7402000.0 (Q1 2026), 5206000.0 (Q4 2025), and 7192000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | -2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.03 Mn |
| Mar 31, 2026 | -7.40 Mn |
| Dec 31, 2025 | -5.21 Mn |
| Sep 30, 2025 | -7.19 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Jun 30, 2024 | -7.35 Mn |
| Mar 31, 2024 | -5.62 Mn |
| Dec 31, 2023 | -11.98 Mn |
| Sep 30, 2023 | -25.42 Mn |
| Jun 30, 2023 | -43.42 Mn |
| Mar 31, 2023 | -33.74 Mn |
| Dec 31, 2022 | -21.67 Mn |
| Sep 30, 2022 | -42.63 Mn |
| Jun 30, 2022 | -50.20 Mn |
| Mar 31, 2022 | -63.63 Mn |
| Dec 31, 2021 | -53.30 Mn |
| Sep 30, 2021 | -52.37 Mn |